Target Name: MIR644A
NCBI ID: G693229
Review Report on MIR644A Target / Biomarker Content of Review Report on MIR644A Target / Biomarker
MIR644A
Other Name(s): hsa-miR-644a | microRNA 644a | MicroRNA 644a | hsa-mir-644 | MIR644 | MIRN644 | hsa-mir-644a

MIR644A: A promising drug target and biomarker for multiple myeloma

Multiple myeloma is a type of cancer that affects the plasma cells, a type of white blood cell that is responsible for producing antibodies. This cancer is characterized by the rapid growth of multiple lymphocytes, which leads to the production of a large number of antibodies and the accumulation of these antibodies in the bone marrow. As a result, multiple myeloma can cause progressive bone pain, fatigue, and anemia. Treatment options for multiple myeloma are limited, and the disease is often treated with chemotherapy, radiation therapy, or targeted therapies. However, new research has identified MIR644A, a non-coding RNA molecule, as a promising drug target and biomarker for multiple myeloma.

MIR644A is a microRNA (miRNA) that is expressed in various tissues and cells, including the bone marrow, spleen, and lymph nodes. It is a non-coding RNA molecule that can interact with other RNA molecules to regulate their stability and translation into proteins. MIR644A has been shown to play a role in the development and progression of various diseases, including cancer.

In multiple myeloma, MIR644A has been shown to be overexpressed, which means that it is produced in greater amounts than it should be. This increase in MIR644A levels can cause it to interact with other RNA molecules and regulate their stability, leading to the production of proteins that are involved in the development and progression of multiple myeloma.

One of the proteins that MIR644A has been shown to interact with in multiple myeloma is BCL2. BCL2 is a protein that has been shown to play a role in regulating the development and survival of various cancers, including multiple myeloma. MIR644A has been shown to bind to the BCL2 protein and regulate its stability, which can lead to the production of more BCL2 proteins. This increase in BCL2 protein levels can further contribute to the development and progression of multiple myeloma.

Another protein that MIR644A has been shown to interact with in multiple myeloma is NF-E2. NF-E2 is a transcription factor that has been shown to play a role in the development and progression of various diseases, including cancer. MIR644A has been shown to bind to the NF-E2 protein and regulate its stability, which can lead to the production of more NF-E2 proteins. This increase in NF-E2 protein levels can further contribute to the development and progression of multiple myeloma.

In addition to its interaction with BCL2 and NF-E2 proteins, MIR644A has also been shown to interact with other RNA molecules that are involved in the development and progression of multiple myeloma. For example, MIR644A has been shown to interact with the protein known as TCF7L1, which is a transcription factor that has been shown to play a role in the development and progression of various diseases, including cancer.

MIR644A has also been shown to interact with the protein known as GAS53, which is a G-protein-coupled receptor (GPCR). GPCR is a protein that has been shown to play a role in the development and progression of various diseases, including cancer. MIR644A has been shown to bind to the GAS53 protein and regulate its stability, which can lead to the production of more GAS53 proteins. This increase in GAS53 protein levels can further contribute to the development and progression of multiple myeloma.

MIR644A has also been shown to interact with the protein known as HSP70, which is a heat shock protein (HSP) that has been shown to play

Protein Name: MicroRNA 644a

The "MIR644A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR644A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR645 | MIR646 | MIR646HG | MIR647 | MIR648 | MIR649 | MIR6499 | MIR650 | MIR6500 | MIR6501 | MIR6502 | MIR6503 | MIR6504 | MIR6505 | MIR6506 | MIR6507 | MIR6508 | MIR6509 | MIR651 | MIR6510 | MIR6511A1 | MIR6511A2 | MIR6511A3 | MIR6511A4 | MIR6511B1 | MIR6511B2 | MIR6512 | MIR6513 | MIR6514 | MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722 | MIR6724-1 | MIR6726 | MIR6727 | MIR6728 | MIR6729 | MIR6730 | MIR6731 | MIR6732 | MIR6733 | MIR6734 | MIR6735 | MIR6736 | MIR6737 | MIR6738 | MIR6739 | MIR6740 | MIR6741 | MIR6742 | MIR6743 | MIR6744 | MIR6746 | MIR6747 | MIR6748 | MIR6749 | MIR675 | MIR6750 | MIR6751 | MIR6752 | MIR6753 | MIR6754 | MIR6755 | MIR6756 | MIR6757 | MIR6758 | MIR6759 | MIR676 | MIR6760 | MIR6761 | MIR6762 | MIR6763